Forte Biosciences Inc
NASDAQ:FBRX
Forte Biosciences Inc
Total Current Liabilities
Forte Biosciences Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
Total Current Liabilities
$13m
|
CAGR 3-Years
78%
|
CAGR 5-Years
40%
|
CAGR 10-Years
9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
See Also
What is Forte Biosciences Inc's Total Current Liabilities?
Total Current Liabilities
13m
USD
Based on the financial report for Sep 30, 2025, Forte Biosciences Inc's Total Current Liabilities amounts to 13m USD.
What is Forte Biosciences Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
9%
Over the last year, the Total Current Liabilities growth was 51%. The average annual Total Current Liabilities growth rates for Forte Biosciences Inc have been 78% over the past three years , 40% over the past five years , and 9% over the past ten years .
